GHRP-2 vs. GHRP-6: Honest Comparison of Two Grey-Market GHRPs

If you spend any time in fitness or longevity forums, you will eventually encounter people comparing GHRP-2 and GHRP-6 as if choosing between them is a straightforward personal preference — like picking between two protein powder flavors. It is not that simple, and the framing is worth pushing back on before you read anything else. Both compounds are synthetic, both are unregulated in the United States, and neither has been approved by the FDA as a drug or dietary supplement. The question of which one is "better" only makes sense after you understand what each actually does to your endocrine system, where the risk profiles differ, and why every major sports authority in the world has banned both substances outright.

Quick verdict: GHRP-2 and GHRP-6 share the same receptor but differ meaningfully in how strongly they drive hunger and how aggressively they were developed toward regulatory approval — GHRP-2 holds a narrow diagnostic approval in Japan, while GHRP-6 never made it that far. Neither is appropriate for unsupervised use, and both are prohibited by WADA.

Both Peptides at a Glance

GHRP-2 and GHRP-6 are both synthetic hexapeptides — six-amino-acid chains — designed to mimic ghrelin, the gut-derived hormone that tells the pituitary gland to release growth hormone. The "GH-releasing peptide" name tells you the mechanism is hormonal rather than direct: you are not injecting GH itself but rather signaling the pituitary to produce its own pulse. That distinction matters for understanding both the appeal and the risk profile.

GHRP-2 is also known as pralmorelin, and under the trade names KP-102 and GPA-748 it underwent clinical development at Kaken and ASKA Pharmaceutical in Japan. A 2004 review in Drugs in R&D catalogued pralmorelin as an "orally active, synthetic growth hormone-releasing peptide" that reached phase 2 trials before receiving a narrow approval in Japan in 1994 — specifically as a diagnostic agent for GH deficiency testing, not as a therapeutic. A diagnostic agent is used once in a controlled clinical setting to confirm whether the pituitary responds normally to GH-stimulating signals. It is not approved for ongoing self-administration.

GHRP-6 has a longer research history and was one of the earliest synthetic growth hormone secretagogues studied extensively in humans, but it never advanced to the same level of regulatory review that pralmorelin reached. Its profile is characterized by a stronger appetite-stimulating effect that has made it a recurring subject of both food intake research and sports anti-doping investigation.

Understanding what peptides are helps frame why these two compounds generate so much discussion: synthetic secretagogues represent an attempt to amplify an existing physiological signal rather than bypass the body's own regulatory machinery. The appeal is real. The evidence for safety at the doses and frequencies used in grey-market settings is not.

How They Work: Shared Receptor, Different Intensity

GHRP-2 and GHRP-6 are both agonists at the growth hormone secretagogue receptor type 1a, commonly abbreviated GHS-R1a. This is the same receptor that endogenous ghrelin binds. When either peptide occupies GHS-R1a, it triggers a cascade that primarily does two things: it stimulates the pituitary to release a pulse of growth hormone, and it activates hypothalamic circuits that regulate hunger and energy balance.

The receptor-binding mechanism is the same for both peptides. What differs is potency and receptor selectivity — and that gap produces the clinical differences that users notice.

GHRP-2 produces a potent GH pulse. A 1997 study in Peptides by Arvat et al. (PMID 9285939) documented that intravenous GHRP-2 in young adults produced GH responses that were "higher (p < 0.05) than that to GHRH" — meaning stronger than growth hormone-releasing hormone itself at the tested doses. That is a significant pharmacological punch. The trade-off is that GHRP-2 is not selective: it also stimulates prolactin, ACTH, and cortisol release, meaning you get a hormonal cascade that extends well beyond GH alone.

GHRP-6 produces a similar pattern of non-selective GHS-R1a agonism. The same study confirmed that GHRP-2 and hexarelin — a related compound — are described as "super-analogs of GHRP-6," suggesting comparable but enhanced potency relative to GHRP-6 at equivalent doses. The critical shared characteristic is that neither peptide is clean: both trigger stress-axis hormones alongside GH release, which is a meaningful distinction from more recently developed secretagogues like ipamorelin.

The Hunger Gap: GHRP-6 Drives Appetite Hard, GHRP-2 Less So

This is the practical difference that most people using these compounds notice within the first administration, and the underlying mechanism explains why it is not a coincidence.

GHS-R1a receptors are heavily expressed in the hypothalamic regions that govern hunger signaling — particularly in the arcuate nucleus, which integrates feeding cues and energy status. Ghrelin itself is sometimes called the "hunger hormone" because fasting causes ghrelin levels to rise sharply, signaling the brain to seek food. Any strong GHS-R1a agonist will activate this pathway to some degree.

GHRP-6 activates the hunger pathway robustly. A 2004 study by Tung, Hewson, and Dickson (PMID 15191362) in European Journal of Endocrinology demonstrated that GHRP-6 significantly increases food intake in animal models, with the effect being "glucocorticoid-dependent" — meaning the appetite-stimulating effect was blunted when corticosterone was absent. This finding links GHRP-6's hunger effect directly to the cortisol-axis stimulation it shares with GHRP-2: the two effects are biochemically coupled.

GHRP-2 also stimulates appetite. A 2005 study in the Journal of Clinical Endocrinology and Metabolism by Laferrere et al. (PMID 15699539) showed that GHRP-2 infusion caused healthy lean men to eat 35.9% more calories compared to saline, and that every participant in the study increased calorie intake regardless of their baseline consumption patterns. So GHRP-2 should not be described as hunger-neutral.

The practical distinction is one of degree. Users and the broader grey-market literature consistently report that GHRP-6 produces a noticeably more aggressive and often uncomfortable hunger surge in the minutes following administration. GHRP-2 produces a measurable appetite effect — the human data confirms this clearly — but the intensity is generally reported as milder. If your goal involves body recomposition or caloric control, that difference in hunger intensity is not trivial and should not be dismissed as anecdote.

Actionable takeaway: If you are evaluating these compounds with a physician and managing caloric intake is a priority, the difference in hunger side-effect intensity between GHRP-6 and GHRP-2 is real, documented, and pharmacologically explained. It is not marketing.

Cortisol and Prolactin: Both Are Non-Selective, Neither Is Clean

One of the more misleading claims circulating in the grey-market peptide space is that GHRP-2 or GHRP-6 are preferable because they avoid the cortisol and prolactin spikes associated with other secretagogues. The scientific record does not support this framing for either peptide.

The Arvat 1997 study (PMID 9285939) is direct: GHRP-2 induces "similar increases in PRL, ACTH and cortisol levels," with ACTH/cortisol activity comparable to human corticotropin-releasing hormone in its clinical effect. The mechanism is GHS-R1a stimulation acting on corticotroph cells in the pituitary — the same receptor activation that releases GH also activates the adrenal axis.

GHRP-6 shares this non-selective profile. Both peptides trigger cortisol and prolactin responses alongside GH release. Chronic cortisol elevation carries a well-documented risk profile including impaired immune function, blood sugar dysregulation, and negative effects on bone density and lean mass — the opposite of what most people using these compounds are trying to achieve.

This is where the comparison to ipamorelin becomes clinically meaningful. A foundational 1998 study by Raun et al. (PMID 9849822) in European Journal of Endocrinology established that ipamorelin "did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation," even at doses more than 200 times the effective GH-releasing dose. The paper explicitly titled ipamorelin "the first selective growth hormone secretagogue" for this reason — and noted that unlike GHRP-6 and GHRP-2, it did not significantly affect prolactin either.

To put that plainly: GHRP-2 and GHRP-6 both activate the stress axis as a side effect of their GH-stimulating mechanism. Ipamorelin was engineered specifically to avoid that. Whether ipamorelin is itself appropriate for use is a separate question governed by the same regulatory concerns — but the selectivity difference is pharmacologically real and frequently understated in grey-market discussions of these compounds.

Actionable takeaway: Anyone presenting GHRP-2 or GHRP-6 as clean-profile secretagogues is misrepresenting the published human data. Cortisol and prolactin effects are documented, not theoretical.

Side-by-Side Comparison

Regulatory Status: What FDA and WADA Actually Say

Neither GHRP-2 nor GHRP-6 is approved by the FDA as a drug or as a dietary supplement. This is not a regulatory technicality — it means neither compound has been evaluated by the FDA for safety or efficacy in the therapeutic or wellness contexts in which grey-market sellers market them.

GHRP-2's closest brush with regulatory approval came in Japan, where pralmorelin received a narrow indication as a diagnostic stimulation agent for GH deficiency testing. A 2022 study in the Journal of the Endocrine Society (PMID 35795807) confirmed that GHRP-2 remains in use in Japan specifically as a clinical diagnostic tool — not as a therapeutic — and that researchers continue to study its ACTH co-stimulation effects as a useful diagnostic feature. The compound's value in this context is precisely that it produces a reproducible hormonal response under controlled conditions in a clinic, with medical supervision and monitoring. That is categorically different from self-injecting it at home based on forum-sourced protocols.

GHRP-6 never reached equivalent regulatory status anywhere. It is a research compound whose clinical development did not advance to regulatory submission.

On the sports and anti-doping front, WADA's prohibited list classifies both compounds explicitly under Section S2.2.4, "Growth Hormone Releasing Factors," covering "GH-releasing peptides (GHRPs)" and naming both GHRP-2 (pralmorelin) and GHRP-6 by name. Both are prohibited at all times — in-competition and out-of-competition — and classified as non-Specified Substances, which carries the highest tier of anti-doping consequences. An athlete who tests positive faces a presumptive four-year ban, not a warning.

Vials sold as "research use only" carry no FDA oversight, no sterility certification, and no guaranteed dosing accuracy. The FDA has issued multiple warning letters to peptide vendors for exactly these violations. Understanding how the peptide safety landscape works is essential context before evaluating any compound in this category.

Actionable takeaway: The Japanese diagnostic approval for GHRP-2 is sometimes cited to imply the compound is safe for self-administration. It does not imply that. A diagnostic agent administered once in a clinic under a physician's supervision is a fundamentally different exposure scenario than repeated self-injection.

Frequently Asked Questions

Does GHRP-2 or GHRP-6 actually increase growth hormone in humans?
Yes, both compounds produce measurable GH pulses in human subjects. The 1997 Arvat study documented GHRP-2 responses exceeding GHRH itself at the tested dose. The open questions are about long-term effects, dose-response at the concentrations used in grey-market contexts, and what happens with repeated administration over weeks or months — data that does not exist from controlled human trials.

Is GHRP-2 safer than GHRP-6?
The published data does not support a clear safety advantage for either compound over the other. GHRP-2's hunger side effects appear milder in most reports, but both produce cortisol and prolactin stimulation, and neither has been evaluated for long-term safety in the doses and frequencies that grey-market users typically apply.

Can I buy GHRP-2 or GHRP-6 legally in the United States?
Both compounds exist in a regulatory grey zone — not FDA-approved as drugs or supplements, frequently sold as "research chemicals" with human-use disclaimers that are a legal hedge rather than a safety guarantee. For athletes subject to WADA or USADA testing, use creates significant risk of a doping violation regardless of the "research" label on the vial.

What did GHRP-2's phase 2 clinical trials actually show?
The clinical development by Kaken and ASKA Pharmaceutical focused on the diagnostic application — testing whether a patient's pituitary would respond normally to GH stimulation. The pharmacological profile (strong GH pulse, cortisol co-stimulation) made it useful as a diagnostic provocative test. The trials did not establish efficacy or safety for therapeutic use in healthy adults, which is the context in which grey-market buyers typically intend to use it.

How do both peptides compare to CJC-1295?
CJC-1295 is a GHRH analog — it acts on a completely different receptor and extends the baseline GH pulse rather than triggering GHS-R1a. GHRP-2 and GHRP-6 are sometimes stacked with CJC-1295 in grey-market protocols because the mechanisms are complementary, which simultaneously multiplies both the potential effects and the unknowns.

Conclusion

GHRP-2 and GHRP-6 have a real mechanism and documented effects on GH secretion in humans. What is absent is evidence that repeated self-administration, sourced from unregulated vendors, produces the health and performance outcomes grey-market proponents claim without meaningful long-term risk.

The honest summary: GHRP-6 drives hunger more intensely than GHRP-2, both trigger cortisol and prolactin responses that ipamorelin was specifically engineered to avoid, GHRP-2 has a narrow Japanese diagnostic approval that does not translate to safety clearance for home use, and both are explicitly named on the WADA prohibited list. Treating which one to choose as the central question skips several more important questions first.

If GH optimization is a legitimate medical goal, those conversations belong with an endocrinologist who can evaluate IGF-1 levels, review your medical history, and prescribe within the boundaries of what the FDA has approved. The grey-market version of that conversation produces a vial with no lot number and a protocol from a forum post.

This article is for informational purposes and not medical advice. Peptides, especially those marketed for therapeutic use, can interact with medications and health conditions. Consult a licensed physician before starting any supplement, particularly if you are pregnant, nursing, taking prescription medications, or managing a chronic condition.